分子診断市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2031年

Persistence Market Research社はこのほど、世界の分子診断市場に関する包括的なレポートを発表しました。本レポートでは、市場促進要因、動向、機会、課題など、主要な市場力学を詳細に分析し、市場構造に関する詳細な洞察を提供しています。

主な洞察

• 分子診断市場規模（2024年）：232億米ドル
• 予測市場規模（2031年）：356億米ドル
• 世界市場成長率（CAGR 2024～2031年）：6.2％

分子診断市場- 調査範囲：

分子診断学は、ゲノムやプロテオーム中の生物学的マーカーを解析し、疾患の診断やモニタリングを行う。この市場には、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、in situハイブリダイゼーションなどの技術が含まれます。分子診断薬は、遺伝性疾患、感染症、特定のがんの診断に不可欠であり、患者固有の疾患プロファイルに関する洞察を提供することで、個別化医療において重要な役割を果たしています。

市場成長の促進要因：

世界の分子診断市場は、遺伝性疾患や感染症の有病率の増加、個別化医療に対する需要の高まりなど、いくつかの重要な要因によって牽引されています。ハイスループット・シーケンシングや高度バイオインフォマティクス・ツールの開発など、分子診断技術の進歩は診断精度と効率を高めています。ヘルスケア支出の増加と予防医療への注目の高まりは、さらに市場の成長に寄与しています。さらに、新興市場における分子診断の拡大や、腫瘍学における分子検査の採用拡大が、市場拡大の新たな機会を生み出しています。

市場抑制要因：

有望な成長見通しにもかかわらず、分子診断市場は高コストと複雑な規制要件に関連する課題に直面しています。先進的な診断機器や検査の価格が高いため、リソースの乏しい環境や新興国におけるアクセスが制限される可能性があります。さらに、分子診断検査の承認と償還のための厳格な規制プロセスは、市場参入を妨げ、技術革新を遅らせる可能性があります。研究開発への継続的な投資の必要性と規制基準の遵守の必要性は、市場成長の大きな障壁となります。

市場機会：

分子診断市場は、技術の進歩、人口動向、ヘルスケアニーズの進化により、大きなビジネスチャンスをもたらしています。携帯型診断機器の開発や診断における人工知能（AI）の統合といった分子診断技術の革新は、市場成長の新たな道を開いています。がん、感染症、遺伝性疾患など、さまざまな治療領域で分子診断の応用が進んでいることが、市場範囲を拡大しています。戦略的パートナーシップ、研究開発への投資、費用対効果の高い診断ソリューションのイントロダクションは、新たなビジネスチャンスを活かし、市場でのリーダーシップを維持するために不可欠です。

本レポートで扱う主な質問

• 分子診断市場の世界的成長を促進する主な要因は何か？
• 様々なヘルスケア環境において、どのような診断技術やアプリケーションが分子診断薬の採用を促進しているか？
• 技術の進歩は分子診断市場の競合情勢をどのように変えているか？
• 分子診断市場に貢献している主要企業はどこか、また市場の関連性を維持するためにどのような戦略を採用しているか？
• 世界の分子診断市場における新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の範囲と定義
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
  • 主な動向
• 分子診断市場：バリューチェーン
  • メーカー一覧
  • 販売代理店一覧
  • 収益性分析
• マクロ経済要因
  • 世界のセクター別展望
  • 世界のGDP成長見通し
  • 世界の親市場概要
• 予測要因- 関連性と影響
• COVID-19の影響評価
• 技術の進歩
• 疾病疫学
• ポーターファイブフォースの分析
• 規制シナリオ
• 製品採用分析
• 親市場分析

第3章 価格動向分析、2024年～2031年

• 主なハイライト
• 製品価格に影響を与える主な要因
• 製品タイプ別の価格
• 地域別の価格と製品の好み

第4章 世界の分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

• 主なハイライト
  • 製品タイプ別の市場規模（単位）予測
  • 市場規模と前年比成長率
  • 絶対的な$機会
• 市場規模の分析と予測
  • 過去の市場規模分析、2019年～2023年
  • 現在の市場規模予測、2024年～2031年
• 世界の分子診断市場の見通し：製品タイプ
  • イントロダクション/主な調査結果
  • 2019年～2023年までの製品タイプ別市場規模と数量（単位）の過去分析
  • 現在の市場規模と製品タイプの数量（ユニット）予測、2024年～2031年
    • 機器
      • ポリメラーゼ連鎖反応（PCR）システム
      • ハイブリダイゼーション（in-situハイブリダイゼーションと魚）システム
      • DNAシーケンシングと次世代シーケンシングプラットフォーム
      • マイクロアレイ
    • 試薬
      • 抗体
      • DNAテンプレート
      • DNAポリメラーゼ
      • オリゴヌクレオチドプライマー
      • デオキシリボヌクレオチド三リン酸（dNTP）
      • バッファ
    • アッセイキット
    • 消耗品
• 市場の魅力分析：製品タイプ
• 世界の分子診断市場の展望：疾患領域
  • イントロダクション/主な調査結果
  • 2019年～2023年における疾病領域別市場規模の歴史的分析
  • 現在の市場規模疾患領域別予測、2024年～2031年
    • 感染症
    • 糖尿病
    • 心臓病学
    • 腫瘍学
    • 腎臓学
    • 自己免疫疾患
    • 皮膚科
    • 創傷ケア
    • その他
• 市場の魅力分析：疾病領域
• 世界の分子診断市場の展望：エンドユーザー
  • イントロダクション/主な調査結果
  • エンドユーザー別市場規模の過去分析、2019～2023年
  • 現在の市場規模エンドユーザー別予測、2024年～2031年
    • 病院・クリニック
    • 診断研究所
    • 学術研究機関
    • バイオ医薬品企業
• 市場の魅力分析：エンドユーザー

第5章 世界の分子診断市場の展望：地域

• 主なハイライト
• 地域別市場規模の過去分析、2019年～2023年
• 現在の市場規模地域別予測、2024年～2031年
  • 北米
  • 欧州
  • 東アジア
  • 南アジアとオセアニア
  • ラテンアメリカ
  • 中東・アフリカ
• 市場の魅力分析：地域

第6章 北米の分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第7章 欧州の分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第8章 東アジアの分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第9章 南アジアおよびオセアニアの分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第10章 ラテンアメリカの分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第11章 中東・アフリカの分子診断市場の展望：過去（2019年～2023年）および予測（2024年～2031年）

第12章 競合情勢

• 市場シェア分析、2024年
• 市場構造
  • 市場別の競合激化マップ
  • 競合ダッシュボード
• 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Hoffmann la roche
  • Qiagen NV
  • Illumina, Inc.
  • DiaSorin SpA
  • Hologic Inc.
  • Siemens Healthineers AG
  • Seegene, Inc.
  • Grifols, SA
  • bioMerieux
  • QuidelOrtho Corporation
  • RapidBio
  • Abbott Laboratories
  • Danaher Corporation

第13章 付録

• 調査手法
• 調査の前提
• 頭字語と略語

Persistence Market Research has recently released a comprehensive report on the global molecular diagnostics market. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, and offers detailed insights into the market structure.

Key Insights:

• Molecular Diagnostics Market Size (2024E): USD 23.2 Bn
• Projected Market Value (2031F): USD 35.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):6.2%

Molecular Diagnostics Market - Report Scope:

Molecular diagnostics involve the analysis of biological markers in the genome and proteome to diagnose and monitor diseases. This market includes technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization. Molecular diagnostics are essential for diagnosing genetic disorders, infectious diseases, and certain cancers, and play a crucial role in personalized medicine by providing insights into patient-specific disease profiles.

Market Growth Drivers:

The global molecular diagnostics market is driven by several key factors, including the increasing prevalence of genetic disorders and infectious diseases, and the growing demand for personalized medicine. Advancements in molecular diagnostic technologies, such as the development of high-throughput sequencing and advanced bioinformatics tools, are enhancing diagnostic accuracy and efficiency. The rise in healthcare expenditures and the increasing focus on preventive healthcare further contribute to market growth. Additionally, the expansion of molecular diagnostics in emerging markets and the growing adoption of molecular tests in oncology are creating new opportunities for market expansion.

Market Restraints:

Despite promising growth prospects, the molecular diagnostics market faces challenges related to high costs and complex regulatory requirements. The high price of advanced diagnostic equipment and tests can limit access in low-resource settings and emerging economies. Additionally, the stringent regulatory processes for approval and reimbursement of molecular diagnostic tests can impede market entry and slow down innovation. The need for continuous investment in R&D and the necessity to comply with regulatory standards pose significant barriers to market growth.

Market Opportunities:

The molecular diagnostics market presents significant opportunities driven by technological advancements, demographic trends, and evolving healthcare needs. Innovations in molecular diagnostic technologies, such as the development of portable diagnostic devices and the integration of artificial intelligence (AI) in diagnostics, are opening new avenues for market growth. The increasing application of molecular diagnostics in various therapeutic areas, including oncology, infectious diseases, and genetic disorders, is expanding the market scope. Strategic partnerships, investments in R&D, and the introduction of cost-effective diagnostic solutions are essential for capitalizing on emerging opportunities and sustaining market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the molecular diagnostics market globally?
• Which diagnostic technologies and applications are driving the adoption of molecular diagnostics in different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the molecular diagnostics market?
• Who are the key players contributing to the molecular diagnostics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global molecular diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global molecular diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic technologies, including next-generation sequencing and real-time PCR systems, catering to diverse diagnostic needs and clinical applications. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practices, and patient education fosters market growth and enhances diagnostic accuracy and outcomes.

Key Companies Profiled:

• Becton, Dickinson and Company
• Bio-Rad Laboratories In
• Merck KgaA
• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc.
• F. Hoffman - La Roche Ltd.
• Illumina, Inc.
• Qiagen N.V.
• Hologic Inc.
• Siemens Healthineers AG
• Seegene, Inc.
• DiaSorin S.p.A
• Grifols, S.A.
• bioMerieux
• QuidelOrtho Corporation
• RapidBio

Molecular Diagnostics Market Research Segmentation

By Product Type:

• Instruments
• Reagent
• Assay Kits
• Consumables

By Disease Area:

• Infectious Disease
• Diabetes
• Cardiology
• Oncology
• Nephrology
• Autoimmune Disease
• Dermatology
• Wound Care
• Others

By End-use:

• Hospitals & Clinics
• Diagnostics Laboratories
• Academic and Research Institutes
• Biopharmaceutical Companies

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Molecular Diagnostics Market Snapshot, 2024 - 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Molecular Diagnostics Market: Value Chain
  • 2.3.1. List of Manufacturers
  • 2.3.2. List of Distributors
  • 2.3.3. Profitability Analysis
• 2.4. Macro-Economic Factors
  • 2.4.1. Global Sectorial Outlook
  • 2.4.2. Global GDP Growth Outlook
  • 2.4.3. Global Parent Market Overview
• 2.5. Forecast Factors - Relevance and Impact
• 2.6. Covid-19 Impact Assessment
• 2.7. Technology Advancement
• 2.8. Disease Epidemiology
• 2.9. Porter Five Force's Analysis
• 2.10. Regulatory Scenario
• 2.11. Product Adoption Analysis
• 2.12. Parent Market Analysis

3. Price Trend Analysis, 2024 - 2031

• 3.1. Key Highlights
• 3.2. Key Factors Impacting Product Prices
• 3.3. Prices by Product Type
• 3.4. Regional Prices and Product Preferences

4. Global Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 4.1. Key Highlights
  • 4.1.1. Market Volume (Units) Projections, by Product Type
  • 4.1.2. Market Size and Y-o-Y Growth
  • 4.1.3. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn ) Analysis and Forecast
  • 4.2.1. Historical Market Size Analysis, 2019-2023
  • 4.2.2. Current Market Size Forecast, 2024 - 2031
• 4.3. Global Molecular Diagnostics Market Outlook: Product Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis by Product Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 4.3.3.1. Instruments
      • 4.3.3.1.1. Polymerase Chain Reaction (PCR) Systems
      • 4.3.3.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 4.3.3.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 4.3.3.1.4. Microarrays
    • 4.3.3.2. Reagent
      • 4.3.3.2.1. Antibodies
      • 4.3.3.2.2. DNA Template
      • 4.3.3.2.3. DNA Polymerase
      • 4.3.3.2.4. Oligonucleotide Primers
      • 4.3.3.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 4.3.3.2.6. Buffer
    • 4.3.3.3. Assay Kits
    • 4.3.3.4. Consumables
• 4.4. Market Attractiveness Analysis: Product Type
• 4.5. Global Molecular Diagnostics Market Outlook: Disease Area
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn ) Analysis By Disease Area, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 4.5.3.1. Infectious Disease
    • 4.5.3.2. Diabetes
    • 4.5.3.3. Cardiology
    • 4.5.3.4. Oncology
    • 4.5.3.5. Nephrology
    • 4.5.3.6. Autoimmune Disease
    • 4.5.3.7. Dermatology
    • 4.5.3.8. Wound Care
    • 4.5.3.9. Others
• 4.6. Market Attractiveness Analysis: Disease Area
• 4.7. Global Molecular Diagnostics Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn ) Analysis by End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 4.7.3.1. Hospitals & Clinics
    • 4.7.3.2. Diagnostics Laboratories
    • 4.7.3.3. Academic and Research Institutes
    • 4.7.3.4. Biopharmaceutical Companies
• 4.8. Market Attractiveness Analysis: End User

5. Global Molecular Diagnostics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn ) Analysis by Region, 2019-2023
• 5.3. Current Market Size (US$ Bn ) Forecast by Region, 2024 - 2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 6.2.1. by Country
  • 6.2.2. by Product Type
  • 6.2.3. By Disease Area
  • 6.2.4. by End User
• 6.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 6.4.1. Instruments
    • 6.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 6.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 6.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 6.4.1.4. Microarrays
  • 6.4.2. Reagent
    • 6.4.2.1. Antibodies
    • 6.4.2.2. DNA Template
    • 6.4.2.3. DNA Polymerase
    • 6.4.2.4. Oligonucleotide Primers
    • 6.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 6.4.2.6. Buffer
  • 6.4.3. Assay Kits
  • 6.4.4. Consumables
• 6.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 6.5.1. Infectious Disease
  • 6.5.2. Diabetes
  • 6.5.3. Cardiology
  • 6.5.4. Oncology
  • 6.5.5. Nephrology
  • 6.5.6. Autoimmune Disease
  • 6.5.7. Dermatology
  • 6.5.8. Wound Care
  • 6.5.9. Others
• 6.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 6.6.1. Hospitals & Clinics
  • 6.6.2. Diagnostics Laboratories
  • 6.6.3. Academic and Research Institutes
  • 6.6.4. Biopharmaceutical Companies
• 6.7. Market Attractiveness Analysis

7. Europe Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 7.2.1. by Country
  • 7.2.2. by Product Type
  • 7.2.3. By Disease Area
  • 7.2.4. by End User
• 7.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 7.4.1. Instruments
    • 7.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 7.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 7.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 7.4.1.4. Microarrays
  • 7.4.2. Reagent
    • 7.4.2.1. Antibodies
    • 7.4.2.2. DNA Template
    • 7.4.2.3. DNA Polymerase
    • 7.4.2.4. Oligonucleotide Primers
    • 7.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 7.4.2.6. Buffer
  • 7.4.3. Assay Kits
  • 7.4.4. Consumables
• 7.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 7.5.1. Infectious Disease
  • 7.5.2. Diabetes
  • 7.5.3. Cardiology
  • 7.5.4. Oncology
  • 7.5.5. Nephrology
  • 7.5.6. Autoimmune Disease
  • 7.5.7. Dermatology
  • 7.5.8. Wound Care
  • 7.5.9. Others
• 7.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 7.6.1. Hospitals & Clinics
  • 7.6.2. Diagnostics Laboratories
  • 7.6.3. Academic and Research Institutes
  • 7.6.4. Biopharmaceutical Companies
• 7.7. Market Attractiveness Analysis

8. East Asia Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 8.2.1. by Country
  • 8.2.2. by Product Type
  • 8.2.3. By Disease Area
  • 8.2.4. by End User
• 8.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 8.4.1. Instruments
    • 8.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 8.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 8.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 8.4.1.4. Microarrays
  • 8.4.2. Reagent
    • 8.4.2.1. Antibodies
    • 8.4.2.2. DNA Template
    • 8.4.2.3. DNA Polymerase
    • 8.4.2.4. Oligonucleotide Primers
    • 8.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 8.4.2.6. Buffer
  • 8.4.3. Assay Kits
  • 8.4.4. Consumables
• 8.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 8.5.1. Infectious Disease
  • 8.5.2. Diabetes
  • 8.5.3. Cardiology
  • 8.5.4. Oncology
  • 8.5.5. Nephrology
  • 8.5.6. Autoimmune Disease
  • 8.5.7. Dermatology
  • 8.5.8. Wound Care
  • 8.5.9. Others
• 8.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 8.6.1. Hospitals & Clinics
  • 8.6.2. Diagnostics Laboratories
  • 8.6.3. Academic and Research Institutes
  • 8.6.4. Biopharmaceutical Companies
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 9.2.1. by Country
  • 9.2.2. by Product Type
  • 9.2.3. By Disease Area
  • 9.2.4. by End User
• 9.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
• 9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 9.4.1. Instruments
    • 9.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 9.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 9.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 9.4.1.4. Microarrays
  • 9.4.2. Reagent
    • 9.4.2.1. Antibodies
    • 9.4.2.2. DNA Template
    • 9.4.2.3. DNA Polymerase
    • 9.4.2.4. Oligonucleotide Primers
    • 9.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 9.4.2.6. Buffer
  • 9.4.3. Assay Kits
  • 9.4.4. Consumables
• 9.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 9.5.1. Infectious Disease
  • 9.5.2. Diabetes
  • 9.5.3. Cardiology
  • 9.5.4. Oncology
  • 9.5.5. Nephrology
  • 9.5.6. Autoimmune Disease
  • 9.5.7. Dermatology
  • 9.5.8. Wound Care
  • 9.5.9. Others
• 9.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 9.6.1. Hospitals & Clinics
  • 9.6.2. Diagnostics Laboratories
  • 9.6.3. Academic and Research Institutes
  • 9.6.4. Biopharmaceutical Companies
• 9.7. Market Attractiveness Analysis

10. Latin America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 10.2.1. by Country
  • 10.2.2. by Product Type
  • 10.2.3. By Disease Area
  • 10.2.4. by End User
• 10.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 10.4.1. Instruments
    • 10.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 10.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 10.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 10.4.1.4. Microarrays
  • 10.4.2. Reagent
    • 10.4.2.1. Antibodies
    • 10.4.2.2. DNA Template
    • 10.4.2.3. DNA Polymerase
    • 10.4.2.4. Oligonucleotide Primers
    • 10.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 10.4.2.6. Buffer
  • 10.4.3. Assay Kits
  • 10.4.4. Consumables
• 10.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 10.5.1. Infectious Disease
  • 10.5.2. Diabetes
  • 10.5.3. Cardiology
  • 10.5.4. Oncology
  • 10.5.5. Nephrology
  • 10.5.6. Autoimmune Disease
  • 10.5.7. Dermatology
  • 10.5.8. Wound Care
  • 10.5.9. Others
• 10.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 10.6.1. Hospitals & Clinics
  • 10.6.2. Diagnostics Laboratories
  • 10.6.3. Academic and Research Institutes
  • 10.6.4. Biopharmaceutical Companies
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 11.2.1. by Country
  • 11.2.2. by Product Type
  • 11.2.3. By Disease Area
  • 11.2.4. by End User
• 11.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 11.4.1. Instruments
    • 11.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 11.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 11.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 11.4.1.4. Microarrays
  • 11.4.2. Reagent
    • 11.4.2.1. Antibodies
    • 11.4.2.2. DNA Template
    • 11.4.2.3. DNA Polymerase
    • 11.4.2.4. Oligonucleotide Primers
    • 11.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 11.4.2.6. Buffer
  • 11.4.3. Assay Kits
  • 11.4.4. Consumables
• 11.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 11.5.1. Infectious Disease
  • 11.5.2. Diabetes
  • 11.5.3. Cardiology
  • 11.5.4. Oncology
  • 11.5.5. Nephrology
  • 11.5.6. Autoimmune Disease
  • 11.5.7. Dermatology
  • 11.5.8. Wound Care
  • 11.5.9. Others
• 11.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 11.6.1. Hospitals & Clinics
  • 11.6.2. Diagnostics Laboratories
  • 11.6.3. Academic and Research Institutes
  • 11.6.4. Biopharmaceutical Companies
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Becton, Dickinson and Company
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Bio-Rad Laboratories Inc
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Thermo Fisher Scientific Inc.
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Merck KGaA
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Agilent Technologies, Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Hoffmann la roche
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Qiagen N.V.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Illumina, Inc.
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. DiaSorin S.p.A
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Hologic Inc.
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Siemens Healthineers AG
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Seegene, Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Grifols, S.A.
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. bioMerieux
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy
  • 12.3.15. QuidelOrtho Corporation
    • 12.3.15.1. Overview
    • 12.3.15.2. Segments and Products
    • 12.3.15.3. Key Financials
    • 12.3.15.4. Market Developments
    • 12.3.15.5. Market Strategy
  • 12.3.16. RapidBio
    • 12.3.16.1. Overview
    • 12.3.16.2. Segments and Products
    • 12.3.16.3. Key Financials
    • 12.3.16.4. Market Developments
    • 12.3.16.5. Market Strategy
  • 12.3.17. Abbott Laboratories
    • 12.3.17.1. Overview
    • 12.3.17.2. Segments and Products
    • 12.3.17.3. Key Financials
    • 12.3.17.4. Market Developments
    • 12.3.17.5. Market Strategy
  • 12.3.18. Danaher Corporation
    • 12.3.18.1. Overview
    • 12.3.18.2. Segments and Products
    • 12.3.18.3. Key Financials
    • 12.3.18.4. Market Developments
    • 12.3.18.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations